Home » Topics » BioWorld Science

BioWorld Science
RSS

SPNS2 inhibition may be useful in treating autoimmune disease

Aug. 10, 2021

NRx initiates phase IIb study of BriLife COVID-19 vaccine in Georgia

Aug. 10, 2021

Otsuka receives a grant for phase II study of OPC-167832 plus delamanid and bedaquiline

Aug. 10, 2021

Trillium initiates dosing of patients with TP53-mutated AML in phase Ib/II study of TTI-622

Aug. 10, 2021

Phase II MERIT study of AXS-05 achieves primary and key secondary endpoints

Aug. 10, 2021

Gruenenthal divulges glucocorticoid receptor modulators

Aug. 10, 2021

New PIN1 inhibitors discovered at Pimedbio, DGMIF

Aug. 10, 2021

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine patent ATR kinase inhibitors

Aug. 10, 2021

Korea Institute of Science and Technology identifies TNK2/MAP4K2 inhibitors

Aug. 10, 2021

First patient dosed in phase Ib/II study of AVB-500 in pancreatic adenocarcinoma

Aug. 10, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.